tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients (tRND&SUDs)
Substance Use Disorder, Attention Deficit Disorder With Hyperactivity, Bipolar Disorder
About this trial
This is an interventional treatment trial for Substance Use Disorder focused on measuring Substance Use Disorder, Attention Deficit Disorder With Hyperactivity, Schizophrenia, Bipolar disorder, Personality disorder
Eligibility Criteria
Inclusion Criteria:
- > 18 years old and less than 60 years
- Best-practice diagnosed Dual Pathology
- Diagnosed since at least two years prior to enrollment.
- Abuse more than 2 Substances
ExclusionC riteria:
- Serious visual and hearing loss
- Brain injury following cranial trauma
- Other neurological disorders like Parkinson, ME, headache, etc.
- Birth trauma
- Mental retardation
- Pregnant
Sites / Locations
- Slow Environment Foundation
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Sham Comparator
tRNS over Anterior Cingulate
tRNS applied over DLPFC
Sham Group
Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
75 patients will be receive tRNS sham 35 sessions.